

<sup>38</sup>  
42. (New) A vector comprising expression regulatory elements operably linked to the nucleic acid molecule, the nucleic acid molecule complementary thereto, or the fragment of claim <sup>37</sup>41.

<sup>39</sup>  
43. (New) A cell transformed with the vector of claim <sup>38</sup>42.

<sup>40</sup>  
44. (New) A cell which produces the non-naturally occurring nucleic acid molecule or nucleic acid molecule complementary thereto or fragment of claim <sup>37</sup>41.

#### REMARKS

This paper cancels claims 1, 20 and 31 without prejudice or disclaimer. This paper also amends claims 14, 15, 16, 17 and 19 and enters new claims 32-44 to more particularly point out and distinctly claim the invention.

No new matter is added in the amended and new claims. Support for the amended claims and the new claims can be found in the specification as indicated below.

Support for the phrase "seven canonical framework residues" of amended claim 14 is found at least at page 31, lines 6-9.

Support for the phrase "75% sequence identity" of amended claim 14 is found at least at page 5, lines 19-23.

Respectfully submitted,



Elie H. Gendloff  
Reg. No. 44,704  
Howell & Haferkamp, L.C.  
7733 Forsyth Boulevard, Suite 1400  
St. Louis, Missouri 63105  
(314) 727-5188

February 1, 2000